Imipenem/Cilastatin Steriscience

Imipenem, the active ingredient in Imipenem/Cilastatin Steriscience, is a carbapenem antibiotic presented as an intravenous injection for hospital use. It treats severe bacterial infections, including intra‑abdominal, urinary, skin and soft‑tissue infections, nosocomial pneumonia, and febrile neutropenia in adult patients, including critically ill patients across various clinical settings.

GNH USA supplies Imipenem/Cilastatin Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Imipenem/Cilastatin is a carbapenem antibiotic used to treat serious bacterial infections. - Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens to resolve infection. - Complicated urinary tract infections: provides broad‑spectrum coverage to achieve bacterial clearance. - Complicated skin and soft‑tissue infections: eliminates resistant organisms and promotes wound healing. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by Gram‑negative and Gram‑positive bacteria. - Febrile neutropenia: offers rapid bactericidal activity to control infection in immunocompromised patients.

Imipenem/Cilastatin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in AST/ALT. - Injection site pain: discomfort at IV site.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Renal toxicity: acute kidney injury in susceptible individuals. - Thrombocytopenia: low platelet count leading to bleeding risk.

Careful assessment and monitoring are required when using Imipenem/Cilastatin to minimize risks. - Renal function: dose adjustment may be needed in patients with impaired kidney function. - Seizure risk: avoid in patients with a history of seizures or CNS disorders unless benefits outweigh risks. - Hypersensitivity: discontinue if signs of allergic reaction such as rash, itching, or anaphylaxis appear. - Concomitant antibiotics: assess for additive toxicity, especially with other nephrotoxic or neurotoxic agents. - Pregnancy and lactation: use only if clearly needed after evaluating potential benefits and risks. - Store at below 25°C: keep in original container, protect from moisture and light.

Imipenem/Cilastatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, risking seizure breakthrough. - Carbapenem antibiotics with probenecid: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance nephrotoxic potential; monitor renal function. - CNS depressants: may increase seizure threshold; observe neurological status. - Anticoagulants: possible alteration of INR; check coagulation parameters regularly.